New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 12, 2013
08:36 EDTIMUCImmunoCellular price target lowered to $12 from $18 at Maxim
Maxim lowered its price target for ImmunoCellular shares to $12 citing pushed out approval assumptions after the company reported ICT-107 trial data. The firm keeps a Buy rating on the stock.
News For IMUC From The Last 14 Days
Check below for free stories on IMUC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
08:19 EDTIMUCLeerink's pharma and biotech analysts hold an analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use